Authors:
Hauck, WW
Parekh, A
Lesko, LJ
Chen, ML
Williams, RL
Citation: Ww. Hauck et al., Limits of 80%-125% for AUC and 70%-143% for C-max - What is the impact on bioequivalence studies?, INT J CL PH, 39(8), 2001, pp. 350-355
Citation: Lj. Lesko et Aj. Atkinson, Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: Criteria, validation, strategies, ANN R PHARM, 41, 2001, pp. 347-366
Authors:
Wang, ZQ
Gorski, C
Hamman, MA
Huang, SM
Lesko, LJ
Hall, SD
Citation: Zq. Wang et al., The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity, CLIN PHARM, 70(4), 2001, pp. 317-326
Authors:
Lesko, LJ
Rowland, M
Peck, CC
Blaschke, TF
Citation: Lj. Lesko et al., Optimizing the science of drug development: Opportunities for better candidate selection and accelerated evaluation in humans, PHARM RES, 17(11), 2000, pp. 1335-1344
Authors:
Lesko, LJ
Rowland, M
Peck, CC
Blaschke, TF
Citation: Lj. Lesko et al., Optimizing the science of drug development: Opportunities for better candidate selection and accelerated evaluation in humans, J CLIN PHAR, 40(8), 2000, pp. 803-814
Authors:
Ibrahim, S
Honig, P
Huang, SM
Gillespie, W
Lesko, LJ
Williams, RL
Citation: S. Ibrahim et al., Clinical pharmacology studies in patients with renal impairment: Past experience and regulatory perspectives, J CLIN PHAR, 40(1), 2000, pp. 31-38
Authors:
Sahi, J
Hamilton, G
Sinz, M
Barros, S
Huang, SM
Lesko, LJ
LeCluyse, EL
Citation: J. Sahi et al., Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes, XENOBIOTICA, 30(3), 2000, pp. 273-284
Authors:
Chen, ML
Lee, SC
Ng, MJ
Schuirmann, DJ
Lesko, LJ
Williams, RL
Citation: Ml. Chen et al., Pharmacokinetic analysis of bioequivalence trials: Implications for sex-related issues in clinical pharmacology and biopharmaceutics, CLIN PHARM, 68(5), 2000, pp. 510-521
Authors:
Marroum, PJ
Uppoor, RS
Parmelee, T
Ajayi, F
Burnett, A
Yuan, R
Svadjian, R
Lesko, LJ
Balian, JD
Citation: Pj. Marroum et al., In vivo drug-drug interaction studies - A survey of all new molecular entities approved from 1987 to 1997, CLIN PHARM, 68(3), 2000, pp. 280-285
Authors:
Davit, B
Reynolds, K
Yuan, R
Ajayi, F
Conner, D
Fadiran, E
Gillespie, B
Sahajwalla, C
Huang, SM
Lesko, LJ
Citation: B. Davit et al., FDA evaluations using in vitro metabolism to predict and interpret in vivometabolic drug-drug interactions: Impact on labeling, J CLIN PHAR, 39(9), 1999, pp. 899-910
Citation: Sm. Huang et al., Assessment of the quality and quantity of drug-drug interaction studies inrecent NDA submissions: Study design and data analysis issues, J CLIN PHAR, 39(10), 1999, pp. 1006-1014
Citation: Gjp. Singh et al., Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modeling, CLIN PHARM, 66(4), 1999, pp. 346-357